TCRT (Alaunos Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)

What is Alaunos Therapeutics OCF Margin %?

Alaunos Therapeutics TCRT -0.18% 28 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates TCRT with a GF Score™ of 28/100 and a GF Value™ of $0.69 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Alaunos Therapeutics ranks worse than 98.33% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Alaunos Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-1.03 Mil. Alaunos Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Alaunos Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Alaunos Therapeutics's current OCF Yield % is -59.56%.

The historical rank and industry rank for Alaunos Therapeutics's OCF Margin % or its related term are showing as below:

TCRT' s OCF Margin % Range Over the Past 10 Years
Min: -602840 Med: -24659.44 Max: -850.09
Current: -104266.67

During the past 13 years, the highest OCF Margin % of Alaunos Therapeutics was -850.09%. The lowest was -602840.00%. And the median was -24659.44%.

TCRT's OCF Margin % is ranked worse than
98.33% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs TCRT: -104266.67

Alaunos Therapeutics OCF Margin % Related Terms

Alaunos Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics OCF Margin % Chart

Alaunos Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-15,444.22

-1,000.41

-602,840.00

-49,710.00

-57,380.00

Alaunos Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															-38,600.00	0.00	0.00	-18,400.00	0.00

TCRT vs ASBP, SILO, PCSA: OCF Margin % Comparison

For the Biotechnology subindustry, Alaunos Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alaunos Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's OCF Margin % falls into.

Save Embed

28GF Score

Alaunos Therapeutics Inc TCRT

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Alaunos Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Alaunos Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-2.869	/	0.005
	=	-57,380.00 %

Alaunos Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-1.031	/	0
	=	%

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of 0.00% mean?

Alaunos Therapeutics (TCRT) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Alaunos Therapeutics and its competitors. According to the industry distribution chart, Alaunos Therapeutics ranks #943 out of 959 companies in the Biotechnology industry, placing it in the top 98.3%.

Is Alaunos Therapeutics' OCF Margin % too high?

Alaunos Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Alaunos Therapeutics ranks #943 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Alaunos Therapeutics' OCF Margin % compare to ASBP and SILO?

According to the Biotechnology industry distribution chart, Alaunos Therapeutics ranks #943 out of 959 companies for OCF Margin %. This places Alaunos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Alaunos Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.69, compared to a current price of $2.15 — trading 211.6% above its estimated fair value. The current OCF Margin % is 0.00%. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $2.15 is trading 211.6% above its estimated GF Value™ of $0.69. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

OCF Margin %: 0.00%
GF Value™: $0.69 vs. price of $2.15 (211.6% above fair value)
GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alaunos Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ASBP SILO PCSA XBIO BCAB LIMN APVO FBLG BGMS CNSP VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301

Website https://www.alaunos.com

Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.

28GF Score

Get the complete analysis for TCRT

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.15

Price

$0.69

GF Value

View TCRT Analysis

See OCF Margin % data for all stocks →